Fetal Bovine Serum Market Trends, Leading Companies, Company Product Portfolio, Vaccine Production Demand, Drug Discovery Adoption, Pricing Trends, Regulatory Compliance, Competitive Landscape, and Growth Outlook

What is the Fetal Bovine Serum Market Size?

The global fetal bovine serum market size is accounted at USD 2.38 billion in 2025 and predicted to increase from USD 2.73 billion in 2026 to approximately USD 9.20 billion by 2035, representing a CAGR of 14.48% from 2026 to 2035. The market is expanding at a solid CAGR of 14.8% over the forecast period 2026 to 2035.

Fetal Bovine Serum Market Key Takeaways

• North America dominated the market in 2025 with a revenue share of 38% and is anticipated to sustain its dominance throughout the forecast period.
• The Asia-Pacific region is expected to record a stable CAGR throughout the estimated period.
• By Application, the vaccine production segment had the largest share during the projection period.
• By Application, the drug discovery segment is assumed to grow a steady CAGR during the predicted period.
• By End-User, the pharmaceuticals and biotechnology industries segment anticipated the dominating spot worldwide.
• By End-User, the research labs segment is predicted to record a constant CAGR during the forecast period.

What is Fetal Bovine Serum?

Fetal bovine serum (FBS) is a nutrient-rich mixture derived from the fetal blood of bovine (cattle) fetuses during the processing of pregnant cows. It is a commonly used supplement in cell culture media to support the growth and survival of many types of cells, including primary cells, mammalian cells, and stem cells. FBS aids drug discovery, production, and development as it prevails in growth properties. It is used for cell attachment to buffer against disruptions such as endotoxins and pH changes. The addition of FBS in the freezing media prevents oxidative stress. Gene and cell therapies rely on many of the same manufacturing approaches, creating a looming possibility in the supply chain of raw materials as recombinant vaccine production. It provides hormones, proteins, vitamins, growth factors, limited antibodies, trace elements, attachment factors, and sheer force of protection.

Fetal Bovine Serum Market Growth Factors

Fetal bovine serum is compatible with a wide range of cell types and can support the growth of both adherent and suspension cultures. It is mainly helpful in cell development, multiplication, and survival. It is extensively utilized in the life science industry, mainly for conducting research. The rapid increase in culture media in developing countries, growth in vaccine production, and increasing product approvals by the regulatory authorities, for instance, Gennova Pharmaceutical's mRNA testing for the Omicron variant, is subjected to regulatory approvals.

Further, in-vitro cell culture in healthcare sectors and the rise in stem cell applications, for example, in treating cancer in the early stage, are responsible for the growth of the fetal bovine serum market. Several events, workshops, and annual meet are organized across the globe to spread awareness about the cell- culture-based vaccine.

The cell culture based vaccine is termed as the vaccine produced from a mammalian cell line rather than embryonic eggs due to their potential benefits in terms of safety, efficacy, and scalability, growing adoption of cell-based therapies, including stem cell therapy and gene therapy, which require fetal bovine serum for cell culture, propelling the market demand. Moreover, cell culture aims to diagnose prevailing infections, conduct research and discover and test new drugs. As the focus on animal cell-based vaccines increases, the demand for FBS also rises, and there is rapid in-vitro production. This factor assists as the trending opportunity for expanding the fetal bovine serum market.

Market Outlook

• Industry Growth Overview: The fetal bovine serum market is experiencing significant growth, driven by fetal bovine serum remains the most versatile and widely used growth supplement in life science labs. Growing R&D in drug discovery, targeted medicine, and cell and gene therapies (like CAR-T) drives demand for high-quality FBS.
• Global Expansion: The market is experiencing significant global expansion, driven by the growing worldwide demand, production, and market for this critical cell culture supplement, driven by biotech research, vaccines, and diagnostics. North America is dominated by strong biotech/pharma industries and advanced research infrastructure.
• Major investors: Major investors in the market are large life science companies such as Thermo Fisher Scientific, Merck KGaA, Danaher (Cytiva/GE Healthcare), and Bio-Techne, alongside specialized suppliers such as HiMedia, Biowest, PAN-Biotech, and Rocky Mountain Biologicals (RMBIO)

Market Scope

Market Dynamics

Drivers

Increasing investments by market players in the life science sector

Soaring research and development activities in the life science industry are determined as the driving factor for the fetal bovine serum market. Regenerative medicine, which involves repairing, replacing, or regenerating damaged tissues or organs, is an emerging field in the life science sector. Fetal bovine serum is commonly used in cell-based therapies and tissue engineering, critical areas of regenerative medicine research. As market players invest more in regenerative medicine research and clinical trials, the demand for FBS as a vital

component in these therapies also increases, driving the FBS market and raising venture capital investment, robust workforce, escalating growth of pharmaceutical industries, and government initiatives to bolster the research in life science.

Restraints

Rise in FBS price while a decrease in its production

Change in variation is a significant concern because of different economic factors but is majorly affected by unreliable sources. Firms need a fixed reference to keep varying prices as there is no regular supply. This leads to some cases of contamination of products where adult bovine serum is blended in to cut the expense. Due to the biochemical contrast that can emerge in FBS due to origin, breed, feed, etc., these variances could be better for scientists who rely entirely on consistency for results.

It has been acknowledged that cattle usage for FBS production has raised the price of FBS in the market. A higher number of cattle are being slaughtered for producing FBS, which according to PETA, has been considered a crime, and the manufacturers are imposed with huge fines, which reduces their production in the market. This price increase is attributed to the substantial surge in demand for FBS and decreased production.

Opportunities

Rising demand for FBS due to the supply gap

FBS is widely available from commercial suppliers and is relatively inexpensive compared to other growth supplements. When the demand for FBS exceeds the available supply, it can lead to an increase in prices. This presents an opportunity for FBS producers and suppliers to capitalize on the price differential and generate higher revenues and profits. Producers may also invest in expanding their production capacity to meet the increased demand and take advantage of favorable market conditions.

The demand and supply gap can stimulate innovation and diversification in the FBS market. Producers may invest in research and development to develop alternative sources of FBS or explore other cell culture media and supplements that can serve as substitutes for FBS. This can create opportunities for new product development and differentiation, leading to a competitive advantage in the market.

Segments Insights

Application Insights

The vaccine production segment is the major revenue contributor and is projected to grow significantly; owing to the rising production of the novel vaccine, FBS provides a rich source of nutrients, hormones, and growth factors essential for cell growth and proliferation. FBS is a vital ingredient in the culture medium that aids in manufacturing vaccines. The introduction of proteomics, genetic engineering, and artificial intelligence in vaccine research propels fetal bovine serum market growth. For instance, according to an article published in AAMC, in March 2021, mRNA technology obliges the reorganization of future vaccines and treatments for infectious diseases and cancer. It can be used to build a diversity of vaccines and therapeutics and is more transient and cost-effective than conventional approaches.

The drug discovery segment is expected to register the fastest growth during the forecast period, owing to the discovery of novel drugs for oncology by using technological advancements such as next-generation proteomics and cell-free DNA for drug discovery and development. For instance, FDA accepted cell-based gene therapy to medicate subjects with Beta-thalassemia that require a regular blood transfusion in August 2022. Further, basic research application is anticipated to garner a significant industry share over the predicted period. Cell-based assays act as the core of life sciences research to better understanding of different cellular events in health and disorders.

End-User Insights

The pharmaceuticals and biotechnology industries segment is the dominant segment in the fetal bovine serum market; the increase in populations across the world dealing with hypertension and diabetes has expanded the growth of a more significant number of pharmaceuticals and biotechnology industries that assign medications for the respective diseases making it to contribute for the highest revenue share in the fetal bovine serum leading to the maximum growth.

The research labs segment held the fastest growing part of the fetal bovine serum market; the growing demand for cell and gene-based research, mainly to oncology and neurodegenerative disorders such as Alzheimer's and Parkinson's disease, aid for the fastest growing segment in the fetal bovine serum market. For instance, the National Institute of Mental Health and Neurosciences (NIMHANS) provides research facilities such as neuro-oncology, cell culture, advanced flow cytometry, etc.

Regional Insights

U.S. Fetal Bovine Serum Market Size and Growth 2026 to 2035

The U.S. fetal bovine serum market size is estimated at USD 640 million in 2025 and is predicted to be worth around USD 2,510 million by 2035, at a CAGR of 14.64% from 2026 to 2035.

North America: High investment and innovation

North America held the largest share of the fetal bovine serum market in 2025, the region is expected to maintain its dominance in the fetal bovine serum market during the predicted period. The presence of maximum leading vital players and a more significant number of private research labs and universities that conduct extensive research and development activities require fetal bovine serum as a crucial component in North America, influencing it to be the dominating region in the world. The United States has better funding facilities, well-established instrumentations, and skilled laborers. Also, it has strict regulations and standards for fetal bovine serum production, ensuring high quality and safety. This has led to the adoption of premium-priced serum products, propelling market growth worldwide.

U.S. Fetal Bovine Serum Market Trends

In the U.S., the presence of well-developed medical care, biotech, and cold-chain distribution networks ensures high-quality FBS supply and consistent delivery. Extensive cattle farming offers a consistent, large-scale source of high-quality bovine blood for serum extraction. Strict quality control and adherence to standards increase trust in North American-sourced FBS.

Europe is anticipating lucrative fetal bovine serum market growth during the predicted period. With emerging cell culture technologies and government initiatives in life science, Europe is home to numerous research institutions and academic centers conducting extensive life science research. Increasing focus on regenerative medicine is promoting the Europe market in fetal bovine serum.

Asia Pacific: Increasing pharmaceutical and biotech growth

The fetal bovine serum market in Asia-Pacific is thriving at a special rate. The increasing usage of fetal bovine serum market in the emerging market is expanding the growth. India is considered the most extensive cattle record after China. With more cattle in the country, the production for FBS margin has increased. Asia-Pacific has a large population, leading to a high demand for vaccines. Fetal bovine serum is extensively used in vaccine production, which is intended to drive the market.

The Latin America- the Middle East & Africa is growing due to increasing demand for vaccines, drugs, and favorable government policies to enhance the industry's development in the fetal bovine serum market. Many countries in Latin America are focusing on improving their healthcare infrastructure, including research and development capabilities, which is expected to boost the demand for fetal bovine serum in the region.

India Fetal Bovine Serum Market Trends

India serves as a key center for biomedical research, particularly in personalized medicine, cell-based therapies, and regenerative medicine, all of which depend heavily on FBS. Robust government support for the life sciences and biotech sectors enhances funding and infrastructure, promoting the adoption of FBS. The presence of major pharmaceutical companies and a growing diagnostics industry spurs high demand for FBS in drug discovery and vaccine development.

Europe: Advanced Research & Development

Europe shows significant growth in the Fetal Bovine Serum Market, driven by strong research infrastructure and an expanding biotech industry. The increasing use of cell-based therapies and the strong demand for fetal bovine serum across drug discovery and R&D, from basic research to specialized assays, further fuel this growth. To specialty assays

The UK Fetal Bovine Serum Market Trends

The UK regulatory system actively funds biomedical research, particularly in areas such as cell therapies, gene therapy, and tissue engineering, which all need significant FBS. The presence of major pharmaceutical organizations and an increasing startup scene in biotech increases the demand for novel drug discovery and clinical trials.

Value Chain Analysis - Fetal Bovine Serum Market

• R&D:
  The R&D and manufacturing process for fetal bovine serum (FBS) involves stringent controls from collection to final testing to ensure a high-quality, consistent product suitable for cell culture.
  Key Players: Thermo Fisher Scientific and Merck KGaA
• Clinical Trials:
  In clinical research and pharmaceutical manufacturing, fetal bovine serum (FBS) is significantly applied as a cell culture supplement to increase and maintain human cells, like stem or immune cells, intended for therapeutic applications.
  Key Players: Bio-Techne
• Manufacturing:
  FBS manufacturing includes rigorous quality control and processing processes to confirm safety and consistency for research and manufacturing applications. These manufacturing and quality assurance processes are crucial because the end products are used by patients.
  Key Players: PAN-Biotech and Corning Incorporated

Competitive Landscape

The fetal bovine serum market is driven by surging demand for advanced biologics and therapeutics, expansion of pharmaceutical R&D budgets, global vaccine growth and emerging markets, and structural supply challenges altering pricing power. The top industrial players are Thermo Fisher Scientific Inc., Merck KGaA, and Danaher Corporation. The major strategic players are Corning Incorporated, GeminiBio, Biowest S.A.S., PAN-Biotech GmbH, and HiMedia Laboratories Pvt. Ltd.

The major products offered by top industries are standard/regular FBS, specialty/application-specific FBS, processed serum, premium-tier FBS, specialty tiers, hybrid solutions, etc. The prominent R&D focus areas are supply chain de-risking, quality standardization, fluorescence and cell tracking technologies, and next-generation cell therapy validation. The top-tier companies have contributed to wide cell culture R&D budgets toward developing chemically defined alternatives and serum-free media.

Company Profiles

TCS Biosciences Ltd

• HQ: Botolph Farm, Botolph Claydon, Buckingham, Buckinghamshire, United Kingdom
• Founded: 1965
• Ownership: Private family-owned company
• Business Overview: TCS Biosciences Ltd offers specialized animal-derived sera for diagnostic, cell culture, and pharmaceutical research applications. The company is committed to mitigating supply chain risks and meeting diverse regulatory requirements.
• Products: Newborn calf serum, donor bovine serum, bovine serum albumin, fully traceable adult and donor cattle serum, etc.
• Geographic Presence: TCS Biosciences Ltd runs versatile operations like laboratory research and development and manufacturing of test kits, reagents, and animal blood/sera products at a rural North Buckinghamshire facility.
• Revenue: TCS Biosciences Ltd generated an annual revenue of approximately $6.4 million.
• Recent Development: TCS Biosciences Ltd reported that the company will present its advanced therapies for 2026, including its portfolio of animal-free cell culture reagents. This will include LowAdhere coating, AntiClump buffer, hydrogels, and recombinant proteins.
• Key Strategies: Quality assurance and regulatory rigor, controlled supply chain, strict certification, commercialising innovation, strategic partnerships and collaboration, animal-free and next-gen cell cultures, resource optimization, strict decarbonisation, pharmaceuticals and human research, food and beverage safety, xeno-free frameworks, and advanced reagents.

Merck KGaA

• HQ: Darmstadt, Germany
• Founded: 1668
• Ownership: Majority-owned by the founding Merck family
• Business Overview: Merck KGaA offers standard, specialized, and fully automated traceable fetal bovine serum grades for diagnostics, academic research, and biopharmaceutical manufacturing. The company maintains high-volume supply capabilities and broad commercial visibility globally.
• Products: The universal supplement for routine mammalian cell culture workflows, high-performance, low-hemoglobin lots for industrial scale-ups and bioprocess applications, cost-effective, premium-grade batches, etc.
• Geographic Presence: Merck KGaA operates in 65 to 66 countries globally with over 62,000 employees. It features major manufacturing sites, hubs, and R&D centers in countries like Japan, India, China, South Korea, and Taiwan.
• Revenue: Merck KGaA generated annual revenue of €21.10 billion for the 2025 financial year.
• Recent Development: In March 2026, Merck KGaA reported net sales around stable at €â€¯21.1 billion, and delivered its consistent focus on sharp strategic focus and disciplined financial performance.
• Key Strategies: High-growth M&A, structural optimization, capitalizing on AI-driven semiconductor microchips, bioconvergence, digitalization, financial resilience, etc.

Gemini Bio-Products

• HQ: West Sacramento, California
• Founded: 1985
• Ownership: Owned by the healthcare private equity firm BelHealth Investment Partners and BroadOak Capital Partners
• Business Overview: Gemini Bio-Products delivers its key offerings, such as cell culture and process liquid solutions, and has expanded its cGMP manufacturing infrastructure and product lines. The company functions as an FDA-registered and ISO 13485-certified medical device manufacturer.
• Products: Acquired legacy brands, highly characterized serum featuring lower endotoxin and hemoglobin thresholds, budget-conscious and performance-reliable standard grades, large-volume, cGMP-manufactured bulk lots, ultra-pure, low-endotoxin serum variations, etc.
• Geographic Presence: Gemini Bio-Products operates its primary manufacturing footprint in the U.S. It also maintains a global commercial and distribution reach.
• Revenue: Gemini Bio-Products reported an estimated annual revenue between $5 million and $25 million
• Recent Development: In February 2026, Gemini collaborated with Tolemy Bio to launch the first AI-enabled media optimization service named aiMOS for cell therapy manufacturing. GeminiBio offers customized media, buffers, serum, and process liquids to advanced therapy and biopharma companies that are dedicated to the research and production of AAV, mRNA, monoclonal antibody, and cell therapy technologies.
• Key Strategies: Scaling agility in cGMP custom manufacturing, regulatory compliance, strict risk segregation, expansion through strategic market acquisitions, and integration of AI-enabled technology.

Thermo Fisher Scientific Inc.

• HQ: Waltham, Massachusetts, United States
• Founded: 1956
• Ownership: Publicly traded company owned by shareholders who hold its stock
• Business Overview: Thermo Fisher Scientific Inc. is the world's leading provider of services like clinical trials, academic research, FBS, and major biopharmaceutical applications. Products strictly adhere to current good manufacturing practice (cGMP) and international ISO standards.
• Products: Gibco Value FBS, Gibco Premium FBS, Gibco Premium Plus FBS, etc.
• Geographic Presence: Thermo Fisher Scientific Inc. operates all over the world with more than 125,000 employees across over 600 sites in Europe, North America, the Middle East and Africa, and the Asia Pacific region.
• Revenue: Thermo Fisher Scientific Inc. reported an annual revenue of $44.56 billion for the 2025 fiscal year.
• Recent Development: In July 2026, Thermo Fisher Scientific Inc. stated that the company is committed to advancing its proven growth strategy and launching innovative, high-impact new products during the quarter. The company has introduced the next-generation Orbitrap platforms with AI-driven analytics at the American Society for Mass Spectrometry conference.
• Key Strategies: High-impact innovation, technology leadership, advanced AI integration, digital ecosystems, strict mergers and acquisitions, scale expansion, and continuous operational improvement.

Moregate Biotech

• HQ: Bulimba, Queensland, Australia
• Founded: 1975
• Ownership: Owned by ANZCO Foods, a major New Zealand red meat and healthcare exporter
• Business Overview: Moregate Biotech strongly focuses on New Zealand-sourced and premium Australian fetal bovine serum (FBS) for biopharmaceuticals and life sciences. It is a key producer of specialized animal-derived biological products and sources its raw materials from Australia and New Zealand.
• Products: Fetal Bovine Serum - Sterile Filtered (FBSF), Fetal Bovine Serum - Sterile Filtered, Gamma Irradiated (FBSF-GI), and defined fetal bovine serum.
• Geographic Presence: Moregate Biotech operates its cGMP manufacturing facilities in New Zealand and Australia, and maintains a strong global footprint rooted in Oceania.
• Revenue: Moregate Biotech reported an estimated annual revenue of $2.8 million for the enterprise scale.
• Recent Development: In May 2026, Moregate Biotech stated that the company operates as a distributor of diversified drugs and has 22 active competitors. It has identified its top competitors, such as EBOS Group, AmerisourceBergen, and Arrow Pharmaceuticals.
• Key Strategies: Disease-free origins, regulatory compliance, supply chain de-risking, rigorous auditing, standardised SOPs, proprietary methods, downstream scaling, direct-to-user global distribution, R&D and process innovation, etc.

Top Companies in the Fetal Bovine Serum Market & Their Offerings

Fetal Bovine Serum Market Companies

• TCS Biosciences Ltd
• Merck KGaA
• Gemini Bio-Products
• Thermo Fischer Scientific Inc.
• Moregate Biotech
• Bovogen Biologicals Pvt Ltd
• General Electric
• Atlanta Biologicals Inc.
• HiMedia Laboratories
• PAN-Biotech
• R&D Systems Inc.

Segments Covered in the Report

By Application

• Cell-based research
• Vaccine production
• Diagnostics
• Drug discovery
• Toxicity testing
• In-vitro fertilization
• Cell therapy

By End-User

• Academic Institutes
• Pharmaceuticals and Biotechnology Industries
• Research labs
• Diagnostic labs
• IVF centers

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa